FAQ

Spryng™ with OsteoCushion™ Technology is a type of biomaterial that is a naturally derived combination of two purified proteins; collagen and elastin bound together in a proprietary process that is used to augment synovial fluid. Spryng™ also works as a cartilage reinforcement for osteoarthritis and other joint issues. It can be used to buffer mechanical malfunction in joints to provide a soft, lubricating, and elastic cushion for the normalization of joint function. Spryng™ is classified as a veterinary medical device. It provides long-lasting relief from the degradation of joint associated with osteoarthritis.

Spryng™ is safe; it was developed for the human market for use as a cosmetic dermal filler. It has been through extensive testing and human trials. It is currently involved in a clinical trial at a major veterinary college. Key opinion leaders and other private practices are evaluating Spryng™ in cases of joint mechanical malfunction as the result of osteoarthritis.

Spryng™ with OsteoCushion™ Technology is comprised of millions of micronized hydrogel matrices, which are derived from the natural components collagen and elastin. OsteoCushion™ Technology provides both reinforcing natural joint support to replace missing or damaged cartilage, and delivers natural scaffolding to tissue defects. Each administration of Spryng™ provides a shock-absorbing matrix with natural fluid biomechanics that work together with synovial fluid to mimic joint cartilage in both form and function. Spryng™ absorbs and releases synovial fluid in response to joint force with elastic stiffness that complements natural synovial fluid and cartilage dynamics. Spryng™ components are sized to remain in the synovial space for long-term benefits after a single treatment. Spryng™ with OsteoCushion™ Technology provides prompt long-term joint reinforcement and protection from regular stress and strain endured by the animal. The components provide a natural scaffold, thus addressing the affliction of lost or damaged cartilage not just masking the symptoms of osteoarthritis.

A veterinary medical device is defined by the FDA as a product that provides function without pharmacological, chemical, or metabolic action. Devices do not have a product infill but have an Instructions for Use (IFU) as a technical guide. Spryng™ is not a drug.

Spryng™ has been initially used in over 600 animals (dogs, horses, rabbits, cats). We are currently involved in several studies on the product looking at efficacy at this time. As these studies are completed and published, PetVivo will provide details on our website. The studies are being conducted at a major university, by reputable private research organizations, and with key opinion leaders.

Spryng™ can only be sold by a licensed veterinarian with an established veterinarian-client-patient relationship (VCPR).

Only a licensed veterinarian can administer Spryng™.

Yes, the product has been used in over 600 animals and continues to be used at an ever-increasing level. There have been many positive case reports in animals suffering from osteoarthritis and other joint afflictions. See equine case studies and small animal case studies.

No, when properly injected Spryng™ stays safely in the synovial space or capsule.

For optimal results, Spryng™ is recommended for animals 6 months of age or older.

Yes, the first reported case-study was use of Spryng™ on a white tiger in a zoo!

The most common joints for the use of Spryng™ are the stifle, hock, fetlock, coffin, and shoulder. Other joints such as tails have been treated with no known adverse effects.

This will depend on the individual animal . . . its underlying issues and health history. In most cases, the animal will respond almost immediately to administration and return to their previous activities, although it may take 7 to 14 days to see the expected response.

Animals can be injected more than once if needed. Spryng™ may last for an extended period in the joint and produce a lasting effect.

Yes, if the opposite joint requires treatment, it can be done during the same procedure. A bilateral treatment may be recommended.

Spryng™ is unique. No other products compare to the naturally derived, distinctive qualities of Spryng™.

Spryng™ with OsteoCushion Technology treats the affliction which is the root cause of the symptom (e.g., pain and inflammation). In other words, Spryng™ addresses the mechanical joint dysfunction and not just the neurological pathways. Many of the products used today only manage pain through pharmacology. Other products that say they treat afflictions may take months to generate a response.

As a veterinary medical device, Spryng™ does not exert pharmacological, chemical, or metabolic injectable devices action. Spryng™ has been used with other products commonly used for osteoarthritis in canines and lameness in horses without known adverse effects. While Spryng™ is a primary tool for managing osteoarthritis, it is one of many excellent tools that should be used in a multi-modal approach.

Though Spryng™ is made from protein materials, processing of the product renders it inert to the immune system of the treated animal.

That will depend on many parameters: the size of the animal, size of the joint, and the severity of the joint dysfunction. Use clinical judgment pertaining to volume needed. Sterile Spryng™ is provided in a 2-mL quantity. The amount of Spryng™ particles should represent the approximate volume of the synovial space as determined by the veterinarian.

Yes, in most cases. Call your pet insurance company and ask for the details. It is best to write detailed medical notes on the diagnosis when applying for reimbursement.

PetVivo manufactures Spryng™ products in the United States under Federal Standards ISO 5 and ISO 7 facilities.

Contact PetVivo at www.info1@petvivo.com or call 844-PET-VIVO (738-8486) to order Spryng™ or arrange communication with our Technical Services Veterinarian.